1387 related articles for article (PubMed ID: 32469434)
21. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
[TBL] [Abstract][Full Text] [Related]
22. Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
Zhang X; Guo X
Ann Hematol; 2019 Sep; 98(9):2223-2225. PubMed ID: 30980106
[No Abstract] [Full Text] [Related]
23. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
[TBL] [Abstract][Full Text] [Related]
24. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Xiu C; Li X; Wu L; Xu F; He Q; Zhang Z; Wu D; Song L; Su J; Zhou L; Zhao Y; Tao Y; Chang C
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3089-3097. PubMed ID: 31559495
[TBL] [Abstract][Full Text] [Related]
26. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
[TBL] [Abstract][Full Text] [Related]
27. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
[TBL] [Abstract][Full Text] [Related]
29. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Assi R; Kantarjian HM; Kadia TM; Pemmaraju N; Jabbour E; Jain N; Daver N; Estrov Z; Uehara T; Owa T; Cortes JE; Borthakur G
Cancer; 2018 Jul; 124(13):2758-2765. PubMed ID: 29660836
[TBL] [Abstract][Full Text] [Related]
30. A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features.
Liu F; Wang H; Liu J; Zhou Z; Zheng D; Huang B; Su C; Zou W; Xu D; Tong X; Li J
Cancer Med; 2019 Sep; 8(11):5108-5115. PubMed ID: 31322840
[TBL] [Abstract][Full Text] [Related]
31. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
Xu J; Xu CG; Liu T; Xiang B; Chang H; He C
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C; Larkin K; Blachly JS; Orwick S; Ngankeu A; Gregory CT; Phelps MA; Mani S; Walker A; Garzon R; Vasu S; Walsh KJ; Bhatnagar B; Klisovic RB; Grever MR; Marcucci G; Byrd JC; Blum W; Mims AS
Am J Hematol; 2020 Dec; 95(12):1457-1465. PubMed ID: 32777116
[TBL] [Abstract][Full Text] [Related]
33. [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Gao S; Qiu H; Jin Z; Tang X; Fu Z; Ma X; Han Y; Chen S; Sun A; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):961-5. PubMed ID: 25417868
[TBL] [Abstract][Full Text] [Related]
34. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
35. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
[TBL] [Abstract][Full Text] [Related]
36. [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Yang XL; Wu YM; Cao YB; Li XH; Xu LX; Liu ZY; Liu B; Yan B; Li SW; DA WM; Wu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1056-61. PubMed ID: 26314446
[TBL] [Abstract][Full Text] [Related]
37. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
Xuan L; Dai M; Jiang E; Wang Y; Huang F; Fan Z; Xu N; Nie D; Liang X; Chen H; Ye J; Shi P; Liu H; Jin H; Lin R; Yan C; Zhang Y; Sun J; Han M; Liu Q
Lancet Haematol; 2023 Mar; 10(3):e178-e190. PubMed ID: 36702138
[TBL] [Abstract][Full Text] [Related]
38. Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Zhao H; Xu L; Yang Y; Shao J; Chen P; Dong X; Gu L; Li D
Acta Haematol; 2017; 137(4):195-200. PubMed ID: 28445872
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
Wu L; Li X; Su J; He Q; Zhang X; Chang C; Pu Q
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1563-9. PubMed ID: 21845438
[TBL] [Abstract][Full Text] [Related]
40. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Ganser A; Heil G; Seipelt G; Hofmann W; Fischer JT; Langer W; Brockhaus W; Kolbe K; Ittel TH; Brack N; Fuhr HG; Knuth P; Höffken K; Bergmann L; Hoelzer D
Ann Hematol; 2000 Jan; 79(1):30-5. PubMed ID: 10663618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
